Baseline characteristics of study population during acute hantavirus infection; CRP C-reactive protein; LDH Lactate dehydrogenase; # Clinical signs and symptoms and laboratory values were taken at time of admission to hospital.

<p>Baseline characteristics of study population during acute hantavirus infection; CRP C-reactive protein; LDH Lactate dehydrogenase; # Clinical signs and symptoms and laboratory values were taken at time of admission to hospital.</p

Characteristics of pre-developed TaqMan reagents.

<p>Characteristics of pre-developed TaqMan reagents.</p

Patient clinical data prior to and on PD.

<p>Patient clinical data prior to and on PD.</p

(A.) CD46, CD55, and CD59 expression in patients on PD based on their history of peritonitis. (B.) Correlation of PD duration and RNA expression of CD46, CD55, and CD59 in patients on PD.

<p>(A.) RNA samples from patients with history of peritonitis (n = 11) and patients without history of peritonitis (n = 13) were analyzed for CD46, CD55, and CD59 by RT-PCR. The mean fold inductions of CD46, CD55, and CD59 were normalized to the housekeeping gene 18SrRNA. There were no significant differences comparing patients with history of PD-associated peritonitis with patients without history of PD-associated peritonitis. (B.) There was no statistically significant correlation between PD duration and the expression of CD46, CD55, or CD55 in patients on PD.</p

Characteristics of applied antibodies.

<p>Characteristics of applied antibodies.</p

IHC of human peritoneal biopsies.

<p>(A.) CD46 staining was strong in mesothelial cells along the peritoneal surface in uremic controls and PD patients. (B.) CD55 was strongly positive in mesothelial cells along the peritoneal surface and in vessels in sub-peritoneal tissues in all groups. (C.) Intensive CD59 staining was observed in mesothelial cells in all groups. Vessels were positive for CD59 in uremic controls and PD patients. All images were taken at 400x.</p

Expression of CD46, CD55 and CD59 using IHC of biopsies from uremic controls (uremic patients at catheter implantation) and patients on peritoneal dialysis (PD).

<p><b>Expression was semiquantitative scored. PD patients were grouped according the D/P ratio creatinine and the D/D0 glucose in patients with low or low average peritoneal transport status (L/LA group) and patients with high average or high transport status (HA/H group)</b>. (A.) No statistically significant difference of CD46 staining between the groups was observed. (B.) CD55 staining was statistically significant decreased between the H/HA and the L/LA group and between the H/HA group and the uremic controls. No statistically significant differences between the L/LA group and the uremic controls could be observed. (C.) CD59 staining did not differ statistically significant between the groups.</p

Expression of CD46, CD55 and CD59 in uremic controls (uremic patients at catheter implantation) and patients on peritoneal dialysis (PD).

<p>PD patients were grouped according the D/P ratio creatinine and the D/D0 glucose in patients with low or low average peritoneal transport status (L/LA group) and patients with high average or high transport status (HA/H group). RNA samples from uremic controls (n = 22), patients on PD in the L/LA-group (L/LA-group, n = 13), and patients on PD in the HA/H-group (HA/H-group, n = 11). CD46, CD55 and CD59 mRNA levels were analyzed by RT-PCR. The mean fold induction of CD46, CD55 and CD59 was normalized to the housekeeping gene 18SrRNA. (A.) There were no statistically significant differences in induction of CD46 RNA expression in PD patients compared to uremic controls and between the L/LA-group compared to the HA/H. (B.) The expression of CD55 was statistically significant decreased in the HA/H-group compared to the L/LA-group and to uremic controls (p < 0.05 and p = 0.05, respectively). (C.) There were no statistically significant differences in induction of CD59 RNA expression in PD patients compared to uremic controls and between patients in the L/LA-group compared to patients in the HA/H-group were detected.</p

A Time course of serum Gamma-GT and AST levels; R Rituximab, A Adalimumab B Antibody titres of the study population.

<p>A Time course of serum Gamma-GT and AST levels; R Rituximab, A Adalimumab B Antibody titres of the study population.</p

Baseline characteristics of patients treated with intravenous immunoglobulins, SLE systemic lupus erythematodes, PID Primary immunodeficiency disease, ITP Idiopathic thrombocytopenic purpura, MDS myelodysplastic syndrome.

<p>Baseline characteristics of patients treated with intravenous immunoglobulins, SLE systemic lupus erythematodes, PID Primary immunodeficiency disease, ITP Idiopathic thrombocytopenic purpura, MDS myelodysplastic syndrome.</p